<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR24">
 <label>24.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Morschhauser</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Fitoussi</surname>
    <given-names>O</given-names>
   </name>
   <name>
    <surname>Haioun</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Thieblemont</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Quach</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Delarue</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Glaisner</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Bosly</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Lister</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Coiffier</surname>
    <given-names>B</given-names>
   </name>
  </person-group>
  <article-title>A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial</article-title>
  <source>Eur J Cancer</source>
  <year>2013</year>
  <volume>49</volume>
  <fpage>2869</fpage>
  <lpage>2876</lpage>
  <pub-id pub-id-type="doi">10.1016/j.ejca.2013.04.029</pub-id>
  <pub-id pub-id-type="pmid">23731832</pub-id>
 </element-citation>
</ref>
